Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
STUDY QUESTION: What are suitable doses of the aromatase inhibitor anastrozole (ATZ) and the progestin levonorgestrel (LNG), when delivered to the systemic circulation by an intravaginal ring (IVR), for further clinical development as a potential new therapy for the treatment of endometriosis? SUMMARY ANSWER: Anticipated targets for pharmacokinetics, pharmacodynamics and safety/tolerability were achieved for both drug components of the IVR at the doses investigated, supporting selection of the doses to be investigated in Phase 2 studies. WHAT IS KNOWN ALREADY: Aromatase is a key enzyme in the biosynthesis of estrogens and is known to increase local levels of estradiol (E2) at extragonadal sites. Up-regulation of aromatase expression has been demonstrated in endometriotic lesions and the use of oral aromatase inhibitors has been shown to reduce endometriosis-associated pelvic pain in small-scale clinical trials. STUDY DESIGN, SIZE, DURATION: This Phase 1, randomized, multicentre, parallel-group, three-arm, open-label study assessed the pharmacokinetics, pharmacodynamics, safety and tolerability of various IVRs intended for systemic drug delivery. After screening, healthy, ovulating women aged 18-35 years were randomized to use IVRs releasing one of the three ATZ/LNG dose combinations (in vitro nominal daily drug release rates on Day 29: ATZ/LNG 500 µg/20 µg [low dose], ATZ/LNG 1000 µg/30 µg [mid dose] or ATZ/LNG 1500 µg/40 µg [high dose]) for two consecutive 28-day wearing periods without a treatment break. PARTICIPANTS/MATERIALS, SETTING, METHODS: Sixty women were included in the per protocol set. The primary variables were plasma concentrations of ATZ and LNG at the end of each treatment period and the mean size of largest follicle-like structures (FLSs) over 56 days. Serum concentrations of several hormones were also evaluated, with emphasis on E2 levels. MAIN RESULTS AND THE ROLE OF CHANCE: At the end of the first treatment period, geometric mean plasma concentrations of LNG and ATZ, respectively, were 0.228 and 12.5 µg/l for the low dose, 0.269 and 19.8 µg/l for the mid dose and 0.384 and 37.3 µg/l for the high dose; results were similar at the end of the second treatment period. Over the entire treatment period, mean FLS sizes were higher in all three treatment groups than during the pretreatment cycle; more women in the mid- and high-dose groups had FLSs of at least 30 mm (32-45%) than those in the low-dose group (14-24%). Changes in the mean size of FLSs were similar to those reported for low-dose progestin-only oral contraceptives and generally resolved during the 2-month treatment period. Serum E2 levels were decreased, but only one woman in each of the mid- and high-dose groups, and no woman in the low-dose group, had a serum E2 level below 20 pg/ml in both cycles. All ATZ and LNG combinations showed good tolerability. LIMITATIONS, REASONS FOR CAUTION: This was an exploratory study; no formal power calculation was performed. WIDER IMPLICATIONS OF THE FINDINGS: The results of this first-in-human study of the ATZ/LNG IVR facilitated the selection of ATZ and LNG doses to be investigated in the Phase 2 studies of patients with endometriosis. STUDY FUNDING/COMPETING INTEREST: The study was funded by Bayer Pharma AG. T.R. is an employee of DINOX GmbH, which received funding from Bayer Pharma AG to perform this study. M.-H.S.-M., K.W., R.N., S.K., J.K., H.S. and B.R. are or have been employees of Bayer Pharma AG. H.S. is a named inventor on EP 2 552 404 B1, a patent application relating to this work. TRIAL REGISTRATION NUMBER: EudraCT number: 2011-005620-18. TRIAL REGISTRATION DATE: 16 November 2011. DATE OF FIRST PATIENT'S ENROLMENT: 14 March 2012.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESHRE guideline: management of women with endometriosis
Dunselman, G. A. J., Vermeulen, N., Becker, C., Calhaz-Jorge, C., D'Hooghe, T., De Bie, B., Heikinheimo, O., Horne, A. W., Kiesel, L., Nap, A., et al. (2014) · Human Reproduction · doi:10.1093/humrep/det457 · Cited by 2,211
Simpson, E. R., Clyne, C., Rubin, G., Boon, W. C., Robertson, K., Britt, K., Speed, C., & Jones, M. (2002) · Annual Review of Physiology · doi:10.1146/annurev.physiol.64.081601.142703 · Cited by 773
Treatment of pelvic pain associated with endometriosis: a committee opinion
(2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.02.012 · Cited by 397
Practice Bulletin No. 114: Management of Endometriosis
(2010) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181e8b073 · Cited by 382
Progestagens and anti-progestagens for pain associated with endometriosis
Brown, J., Kives, S., & Akhtar, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002122.pub2 · Cited by 250
Advances in the management of endometriosis: an update for clinicians
Crosignani, P., Olive, D., Bergqvist, A., & Luciano, A. (2006) · Human Reproduction Update · doi:10.1093/humupd/dmi049 · Cited by 237
Soysal, S. (2004) · Human Reproduction · doi:10.1093/humrep/deh035 · Cited by 227
Gonadotrophin-releasing hormone analogues for pain associated with endometriosis
Veth, V. B., van de Kar, M. M., McDonnell, R., Julania, S., & Hart, R. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008475.pub2 · Cited by 182
Endometriosis: Current Therapies and New Pharmacological Developments
Vercellini, P., Somigliana, E., Viganò, P., Abbiati, A., Barbara, G., & Crosignani, P. G. (2009) · Drugs · doi:10.2165/00003495-200969060-00002 · Cited by 182
Oral contraceptives and risk of endometriosis: a systematic review and meta-analysis
Vercellini, P., Eskenazi, B., Consonni, D., Somigliana, E., Parazzini, F., Abbiati, A., & Fedele, L. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmq042 · Cited by 176
Research works printed but not linked: 27
- 10.1016/j.fertnstert.2011.07.1136 · DOI · Paper page
- 10.1016/j.fertnstert.2003.09.029 · DOI · Paper page
- 10.1016/j.fertnstert.2005.02.018 · DOI · Paper page
- Barbieri, 1998, Endometriosis and the estrogen threshold theory. Relation to surgical and medical treatment, J Reprod Med, 43, 287
- Bartley, 2014, A safety and efficacy study on long term treatment with letrozole after GnRH: a down-regulation in premenopausal patients with moderate and severe endometriosis, Hum Reprod, 29, i196
- 10.1016/0010-7824(85)90096-4 · DOI
- 10.1677/jme.0.0250035 · DOI · Paper page
- 10.1093/humupd/6.5.413 · DOI · Paper page
- 10.1016/0010-7824(87)90014-X · DOI
- Davis L , Kennedy SS , Moore J , Prentice A . Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2007;2:CD001019. · DOI · Paper page
- 10.1038/sj.bjc.6690050 · DOI
- 10.1054/bjoc.2001.1925 · DOI
- 10.1093/humrep/dep302 · DOI · Paper page
- 10.1038/bjc.1996.531 · DOI · Paper page
- Higa, 1998, Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer, Am J Health Syst Pharm, 55, 445, 10.1093/ajhp/55.5.445 · doi:10.1093/ajhp/55.5.445
- 10.1016/0010-7824(93)90025-3 · DOI
- 10.1158/0008-5472.CAN-09-3024 · DOI
- Insler, 1972, The cervical score A simple semiquantitative method for monitoring of the menstrual cycle, Int J Gynaecol Obstet, 10, 223, 10.1002/j.1879-3479.1972.tb00857.x · DOI · Paper page
- 10.2165/00003495-200666170-00001 · DOI
- 10.1007/BF00682745 · DOI · Paper page
- 10.1111/j.1479-828X.2007.00722.x · DOI · Paper page
- 10.1093/humrep/14.4.982 · DOI · Paper page
- 10.1093/humrep/deu315 · DOI
- 10.1016/j.fertnstert.2004.04.059 · DOI
- 10.1016/S0015-0282(97)00193-3 · DOI · Paper page
- 10.5414/CPP48563 · doi:10.5414/cpp48563
- 10.2165/00002512-199813040-00008 · DOI
Cited by
Medical treatment of endometriosis-related pain
Vercellini, P., Buggio, L., Frattaruolo, M. P., Borghi, A., Dridi, D., & Somigliana, E. (2018) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2018.01.015 · Cited by 188
Current and emerging treatment options for endometriosis
Ferrero, S., Evangelisti, G., & Barra, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494154 · Cited by 152
Androgens, oestrogens and endometrium: a fine balance between perfection and pathology
Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0106 · Cited by 76
Mercorio, A., Giampaolino, P., Romano, A., Dällenbach, P., & Pluchino, N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.950866 · Cited by 16
“Phase I and Phase II studies on an IVR containing a combination of anastrazole and levonorgestrel gave reassuring results in terms of safety and tolerability at different doses as well as contraceptive efficacy (35, 36).”
Background
Metadata
- Authors
- Schultze-Mosgau, M.-H., Waellnitz, K., Nave, R., Klein, S., Kraetzschmar, J., Rautenberg, T., Schmitz, H., & Rohde, B.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-06-19
- Volume
- 31
- Issue
- 8
- Pages
- 1713-1722
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2468144665
- Cited by
- 31
- References
- 11
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Bayer Pharma AG
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.